Human Pathology
Volume 41, Issue 2 , Pages 199-207 , February 2010

Does protein expression predict recurrence of benign World Health Organization grade I meningioma?

  • Vesa Kärjä, MD, PhD

      Affiliations

    • Department of Clinical Pathology, Kuopio University Hospital, 70211 Kuopio, Finland
    • Department of Clinical Pathology and Forensic Medicine, Institute of Clinical Medicine, University of Kuopio, 70211 Kuopio, Finland
    • ,
  • Pär-Johan Sandell, MD

      Affiliations

    • Department of Neurosurgery, Kuopio University Hospital, 70211 Kuopio, Finland
    • ,
  • Tarja Kauppinen

      Affiliations

    • Department of Neurology, Institute of Clinical Medicine, University of Kuopio, 70211 Kuopio, Finland
    • ,
  • Irina Alafuzoff, MD, PhD

      Affiliations

    • Department of Clinical Pathology, Kuopio University Hospital, 70211 Kuopio, Finland
    • Department of Neurology, Institute of Clinical Medicine, University of Kuopio, 70211 Kuopio, Finland
    • Department of Pathology and Genetics, Uppsala University, 75185 Uppsala, Sweden
    • Corresponding Author InformationCorresponding author. Unit of Neurology, Section of Neuropathology, Department of Clinical Medicine, Kuopio University, PO Box 1627, 70211 Kuopio, Finland.

Received 25 March 2009 ,Revised 27 May 2009 ,Accepted 23 June 2009.

References 

  1. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol. 1986;26:461–469
  2. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986;25:233–242
  3. Aguiar PH, Tsanaclis AM, Tella OI, Plese JP. Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics. Neurosurg Rev. 2003;26:221–228
  4. Amatya VJ, Takeshima Y, Sugiyama K, et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol. 2001;32:970–975
  5. Devaprasath A, Chacko G. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas. Neurol India. 2003;51:336–340
  6. Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer. 2002;94:1538–1547
  7. Kalala JP, Caemaert J, De Ridder L. Primary resected meningiomas: relapses and proliferation markers. In Vivo. 2004;18:411–416
  8. Matsuno A, Nagashima T, Matsuura R, et al. Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas. Am J Clin Pathol. 1996;106:776–781
  9. Torp SH, Lindboe CF, Gronberg BH, Lydersen S, Sundstrom S. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin Neuropathol. 2005;24:170–174
  10. Maiuri F, De Caro Mdel B, Esposito F, et al. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol. 2007;82:63–68
  11. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology. 2007;27:114–120
  12. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology. 2007;27:407–412
  13. Konstantinidou AE, Korkolopoulou P, Kavantzas N, et al. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. Histol Histopathol. 2003;18:67–74
  14. Konstantinidou AE, Patsouris E, Korkolopoulou P, Kavantzas N, Mahera H, Davaris P. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas. Histopathology. 2001;39:402–408
  15. Korshunov A, Shishkina L, Golanov A. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. Arch Pathol Lab Med. 2002;126:1079–1086
  16. Hunt DP, Freeman A, Morris LS, et al. Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br J Neurosurg. 2002;16:10–15
  17. Kalala JP, Maes L, Vandenbroecke C, de Ridder L. The hTERT protein as a marker for malignancy in meningiomas. Oncol Rep. 2005;13:273–277
  18. Maes L, Lippens E, Kalala JP, de Ridder L. The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Prolif. 2005;38:3–12
  19. Smith JS, Lal A, Harmon-Smith M, Bollen AW, McDermott MW. Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg. 2007;106:1034–1040
  20. Martinez-Rumayor A, Arrieta O, Guevara P, et al. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett. 2004;213:117–124
  21. Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol. 2006;37:415–421
  22. Ucar T, Gurer I. Prognostic importance of transferrin receptor expression and correlation with K1-67 labelling indices in intracranial meningiomas. Br J Neurosurg. 2003;17:525–529
  23. Hakin-Smith V, Battersby RD, Maltby EL, Timperley WR, Royds JA. Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence. Neuropathol Appl Neurobiol. 2001;27:40–49
  24. Konstantinidou AE, Pavlopoulos PM, Patsouris E, Kaklamanis L, Davaris P. Expression of apoptotic and proliferation markers in meningiomas. J Pathol. 1998;186:325–330
  25. Muller P, Henn W, Niedermayer I, et al. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res. 1999;5:3569–3577
  26. Bouvier C, Liprandi A, Colin C, et al. Lack of alkaline phosphatase activity predicts meningioma recurrence. Am J Clin Pathol. 2005;124:252–258
  27. Verheijen FM, Donker GH, Viera CS, et al. Progesterone receptor, bc1-2 and bax expression in meningiomas. J Neurooncol. 2002;56:35–41
  28. Okamoto H, Li J, Vortmeyer AO, et al. Comparative proteomic profiles of meningioma subtypes. Cancer Res. 2006;66:10199–10204
  29. Levicar N, Strojnik T, Kos J, Dewey RA, Pilkington GJ, Lah TT. Lysosomal enzymes, cathepsins in brain tumor invasion. J Neurooncol. 2002;58:21–32
  30. Trinkaus M, Vranic A, Dolenc VV, Lah TT. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers. 2005;20:50–59
  31. Strojnik T, Zidanik B, Kos J, Lah TT. Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery. 2001;48:598–605
  32. Konstantinidou AE, Korkolopoulou P, Mahera H, et al. Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology. 2003;43:280–290
  33. Strik HM, Strobelt I, Pietsch-Breitfeld B, Iglesias-Rozas JR, Will B, Meyermann R. The impact of progesterone receptor expression on relapse in the long-term clinical course of 93 benign meningiomas. In Vivo. 2002;16:265–270
  34. Wolfsberger S, Doostkam S, Boecher-Schwarz HG, et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev. 2004;27:238–245
  35. Kuusisto E, Kauppinen T, Alafuzoff I. Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol. 2008;34:169–180
  36. Karja V, Alafuzoff I. Protein p62 common in invaginations in benign meningiomas–a possible predictor of malignancy. Clin Neuropathol. 2006;25:37–43
  37. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22–39

☆ This study has been supported by EVO grants from the Kuopio University Hospital.

PII: S0046-8177(09)00261-5

doi: 10.1016/j.humpath.2009.06.020

Human Pathology
Volume 41, Issue 2 , Pages 199-207 , February 2010

Article Tools

* Image Usage & Resolution